Canada’s Université de Montréal is recruiting businesses to supplement traditional government grants for cancer research on its campus. The university’s Institute for Research in Immunology and Cancer (IRIC) models this program on a similar partnership that funded Canadian athletes for the 2010 Winter Olympics.
The new program, called B2Discovery, hopes to enlist the for-profit private sector to fund research into cancer causes, diagnostics, drugs for prevention, and therapies for cures. According to Dr. Guy Sauvageau, CEO and Scientific Director of IRIC, the private funding will supplement traditional government funding, which Sauvageau says in a news release today “meets only part of the needs of our researchers.”
The model for B2Discovery is the B2Ten program, which supplements athletes’ main sources of funding, providing access to the extra training and services athlete’s need to excel internationally. B2Ten’s private-sector funds supported some 20 athletes that competed for Canada at the Vancouver Olympics. Like the B2Ten program, enterprises make charitable contributions to B2Discovery and take no ownership of the research findings.
B2Discovery is attracting interest from companies beyond biomedical industries. One of the early backers is Pomerleau, a construction company based in Saint-Georges, Quebec. Pierre Pomerleau, the company’s president, says they signed on to B2Discovery because of its important mission and the role business can play. “Cancer is the leading cause of mortality in the country,” Pomerleau says. “To conquer this devastating disease, we must be innovative.”